ArticleMolecular biology research communications2022
Correlation between adiponectin rs2241766 and rs266729 polymorphisms and risk of papillary thyroid cancer.
Article in Molecular biology research communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- Exploring the impact of ADIPOQ gene variants on plasma adiponectin levels and oxidative stress in type 2 diabetes mellitus and diabetic nephropathy in South Indian population: a case-control study.Diabetology international · 2025Article
- Diabetes Mellitus and Thyroid Cancers: Risky Correlation, Underlying Mechanisms and Clinical Prevention.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
About 60-80% of thyroid cancer (TC) cases are papillary thyroid cancer (PTC). Studies have shown that serum adiponectin levels are inversely related to the risk of TC and PTC. Aim of the present study was to evaluate the association between adiponectin rs2241766 and rs266729 polymorphisms and risk of PTC. 122 PTC patients and 128 healthy subjects were enrolled in the study. PCR-RFLP and ARMS-PCR methods were used for genotype analysis. The rs266729 polymorphism did not correlate with risk of PTC. As regard rs2241766 polymorphism, the frequency of the GG genotype did not have a significant difference between the two groups, although, PTC cases showed higher frequency of GT genotype compared to controls (OR=2.87, 95% CI=1.56-5.28, P=0.001). We observed a significant association between adiponectin rs2241766 polymorphism and PTC, however, our result showed no significant relationship between adiponectin rs266729 polymorphism and risk of PTC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.